KAMRF yields 1818.18% · JNJ yields 2.13%● Live data
📍 KAMRF pulled ahead of the other in Year 1
Combined, KAMRF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KAMRF + JNJ for your $10,000?
Kalamazoo Resources Limited explores for and develops gold and base metal properties in Australia. The company also explores for nickel and cobalt deposits. It holds interests in the Castlemaine project that consists of three exploration licenses covering an area of approximately 310 square kilometers; the South Muckleford project that comprises an area of approximately 161 square kilometers; the Tarnagulla project; and the Myrtle project located in Victoria. The company also holds interests in the Pilbara projects, including the Ashburton project comprising 4 mining leases and 3 exploration licenses covering an area of approximately 217 square kilometers; the DOM's Hill project that covers an area of approximately 125 square kilometers; the Marble Bar project covering an area of approximately 125 square kilometers; the Pear Creek lithium project covering an area of approximately 147 square kilometers; and the Sisters project covering an area of approximately 239 square kilometers situated in Western Australia. Kalamazoo Resources Limited was incorporated in 2011 and is headquartered in West Perth, Australia.
Full KAMRF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.